Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | FAAH | O00519 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | BCL2 | P10415 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4927603 | 0.92 | KMT2A (0.49) | CA9FAAHTP53KMT2AGAA | |
| SCHEMBL5269424 | 0.90 | CA9 (0.46) | CA9FAAHTP53KMT2AGAA | |
| SCHEMBL5521982 | 0.89 | ALDH1A1 (0.48) | CA9FAAHTP53KMT2AGAA | |
| SCHEMBL5162940 | 0.87 | MDM2 (0.51) | KMT2ABCL2MDM2MCL1MEN1 | |
| SCHEMBL4927623 | 0.83 | MDM2 (0.57) | CA9FAAHTP53KMT2AGAA | |
| SCHEMBL4930082 | 0.82 | KMT2A (0.55) | CA9FAAHTP53KMT2AGAA | |
| SCHEMBL4923024 | 0.79 | KMT2A (0.52) | CA9FAAHTP53KMT2AGAA | |
| SCHEMBL5163560 | 0.79 | MARS1 (0.46) | KMT2ABCL2MDM2MCL1MEN1 | |
| SCHEMBL27668640 | 0.79 | RPA1 (0.42) | KMT2ABCL2MDM2MCL1MEN1 | |
| SCHEMBL16597799 | 0.78 | KMT2A (0.55) | CA9TP53KMT2AGAABCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
| EP-1698626-A1 | AMIDOPYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064682-A1 | Pyrazole Derivatives | NAT1, AR, CBR3 | CA9 1503/4885FAAH 2841/4885TP53 3440/4885 |
| US-20070219210-A1 | Amidopyrazole Derivative | PTGER1, PTGS1, PTGER2 | CA9 3499/4885FAAH 63/4885TP53 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.